Pathology Outlines - PRAME PRAME (preferentially expressed antigen in melanoma) is a cancer testis antigen expressed by melanoma and other malignant neoplasms with expression in normal tissue largely restricted to testis
What is PRAME? | MyPathologyReport PRAME stands for “preferentially expressed antigen in melanoma ” It is a special type of protein called a cancer-testis antigen This means that PRAME is usually found in cancer cells and normal cells within the testis, but rarely in other normal tissues of the body
PRAME - Wikipedia PRAME (preferentially expressed antigen of melanoma) is a protein that in humans is encoded by the PRAME gene [3][4][5] Five alternatively spliced transcript variants encoding the same protein have been observed for this gene
PRAME Expression in Melanocytic Tumors - PMC PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen that was isolated by autologous T cells in a melanoma patient
PRAME Shows Promise as a Treatment Avenue in . . . - OncLive As investigators continue to refine and carve out a role for targeted therapies in the treatment paradigm across tumor types, preferentially expressed antigen in melanoma (PRAME) has emerged as
Preferentially Expressed Antigen in Melanoma (PRAME . . . Preferentially expressed antigen in melanoma (PRAME) is a cancer-testis antigen that is minimally expressed in adult human tissues other than gonads but is present in various human cancers including melanoma and some sarcomas (1–6)
PRAME Expression in Cancer. A Systematic Immunohistochemical . . . Preferentially expressed antigen in melanoma (PRAME) is considered a useful marker in the differential diagnosis between malignant melanoma and its melanocytic mimics Recently PRAME expression was documented in nonmelanocytic tumors, but much of the data are based on mRNA studies
Test Definition: PRAME - Mayo Clinic Laboratories PRAME (Preferentially expressed Antigen in Melanoma) expression in melanocytic neoplasms is strongly associated with melanoma and may be useful in differentiating benign nevi from malignant melanocytic lesions